{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:26:43Z","timestamp":1770492403492,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.109984","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T13:00:14Z","timestamp":1591794014000},"page":"109984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy"],"prefix":"10.1016","volume":"144","author":[{"given":"Nehru Sai Suresh","family":"Chalichem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharathi","family":"Bethapudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Mundkinajeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.109984_b0005","unstructured":"https:\/\/www.nutraceuticalsworld.com\/issues\/2020-05\/view_trendsense\/getting-ahead-of-the-curve-immunity-in-the-new-normal\/."},{"key":"10.1016\/j.mehy.2020.109984_b0010","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3389\/fmicb.2018.02407","article-title":"Andrographolide prevents EV-D68 replication by inhibiting the acidification of virus-containing endocytic vesicles","volume":"9","author":"Wang","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109984_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40199-015-0119-4","article-title":"Dehydroandrographolide enhances innate immunity of intestinal tract through up-regulation the expression of hBD-2","volume":"23","author":"Xiong","year":"2015","journal-title":"DARU J Pharm Sci"},{"issue":"3","key":"10.1016\/j.mehy.2020.109984_b0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1753425910365734","article-title":"Defensins and cathelicidins in lung immunity","volume":"16","author":"Tecle","year":"2010","journal-title":"Innate Immun"},{"issue":"5","key":"10.1016\/j.mehy.2020.109984_b0025","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.4049\/jimmunol.180.5.3319","article-title":"Airway epithelial versus immune cell Stat1 function for innate defense against respiratory viral infection","volume":"180","author":"Shornick","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109984_b0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00425-002-0902-6","article-title":"Plant defensins","volume":"216","author":"Thomma","year":"2002","journal-title":"Planta"},{"issue":"8","key":"10.1016\/j.mehy.2020.109984_b0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00109-005-0657-1","article-title":"Human defensins","volume":"83","author":"Schneider","year":"2005","journal-title":"J Mol Med"},{"issue":"9","key":"10.1016\/j.mehy.2020.109984_b0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.humimm.2013.05.008","article-title":"Defensins: natural component of human innate immunity","volume":"74","author":"Jarczak","year":"2013","journal-title":"Hum Immunol"},{"issue":"40","key":"10.1016\/j.mehy.2020.109984_b0045","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1002\/anie.201402167","article-title":"The chemistry and biology of theta defensins","volume":"53","author":"Conibear","year":"2014","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"10.1016\/j.mehy.2020.109984_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000095","article-title":"Reawakening retrocyclins: ancestral human defensins active against HIV-1","volume":"7","author":"Venkataraman","year":"2009","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109984_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkh309","article-title":"Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis","volume":"54","author":"Schultz","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.mehy.2020.109984_b0060","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1136\/thx.54.2008.S58","article-title":"The anti-inflammatory effects of macrolides","volume":"54","author":"Wales","year":"1999","journal-title":"Thorax"},{"issue":"21","key":"10.1016\/j.mehy.2020.109984_b0065","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1128\/JVI.01363-09","article-title":"Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease","volume":"83","author":"Wohlford-Lenane","year":"2009","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.mehy.2020.109984_b0070","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/AAC.00267-11","article-title":"Humanized \u03b8-defensins (retrocyclins) enhance macrophage performance and protect mice from experimental anthrax infections","volume":"55","author":"Welkos","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.mehy.2020.109984_b0075","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.4049\/jimmunol.1101335","article-title":"Hapivirins and diprovirins: novel \u03b8-defensin analogs with potent activity against influenza A virus","volume":"188","author":"Doss","year":"2012","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.mehy.2020.109984_b0080","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1086\/521027","article-title":"\u03b2-defensin inhibits influenza virus replication by cell-mediated mechanism (s)","volume":"196","author":"Salvatore","year":"2007","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.mehy.2020.109984_b0085","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.4049\/jimmunol.178.12.8046","article-title":"Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses","volume":"178","author":"Tecle","year":"2007","journal-title":"J Immunol"},{"issue":"32","key":"10.1016\/j.mehy.2020.109984_b0090","doi-asserted-by":"crossref","first-page":"27014","DOI":"10.1074\/jbc.R112.346098","article-title":"\u03b8-Defensins: cyclic peptides with endless potential","volume":"287","author":"Lehrer","year":"2012","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.mehy.2020.109984_b0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri1860","article-title":"Defensins in innate antiviral immunity","volume":"6","author":"Klotman","year":"2006","journal-title":"Nat Rev Immunol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720311440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720311440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:23:50Z","timestamp":1759692230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720311440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":19,"alternative-id":["S0306987720311440"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109984","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109984"}}